Floatz logo

Regorafenib

Advanced Colorectal Adenocarcinoma

City of Hope Medical CenterSmall moleculePhase 2Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

66 Active assets in the Advanced Colorectal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Trifluridine
Centre Hospitalier Universitaire Dijon
Phase 3BB
Botensilimab
City of Hope Medical Center
Phase 2BB
Balstilimab
City of Hope Medical Center
Phase 2BB
FLUOROURACILUM
Centre Hospitalier Universitaire Dijon
Phase 3BB
Eloxatin
Pfizer
Phase 3BB

View all 50 →

Same molecule, other indications

Regorafenib is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
RegorafenibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →